Cancer Drug Costs, Part B Demo, and Value-Base Care
The Colombian government moved to reduce the cost of the cancer drug Gleevec, in an effort to make the medication more affordable to its citizens.
“Ono Pharmaceutical Co. cut its annual profit outlook by a quarter on Wednesday, hit by the Japanese government’s decision to halve the price of cancer drug Opdivo”
Since 1965 there has been a 100-fold increase in cancer drug costs. Since 1990,the cost for new cancer drugs has gone up ten-fold.
Forbes reports that they expect Trump’s nomination for HHS to slow the move toward value based care.
In this article ASCO reports that CMS has decided not to move forward with the Part B demo, but looks forward to working with the new administration to create beneficial policies.